高华 教授
硕士招生类型：学术型
硕士招生专业：基础医学
博士招生类型：学术型
博士招生专业：临床医学（基础医学方向）
所在院系：附属第十人民医院
联系方式：gaoh@tongji.edu.cn
课题组链接：
研究方向
主要任职
科研业绩

肿瘤转移（Cancer Metastasis）

2019/05－ ： 教授、研究员，博导，上海第十人民医院/同济大学医学院/转化医学高等研究院
2013/02－2019/04： 教授、研究员，博导，转化医学高等研究院/同济大学生科院/上海东方医院
2004/08－2013/01：Senior Research Scientist，Research Associate，ResearchScholar, Research Fellow Memorial Sloan Kettering Cancer Center
2003－2004： Research Fellow中国科学院上海生命科学研究院生化与细胞研究所
1998－2003： 博士，中国科学院上海生命科学研究院生化与细胞研究所
1996－1998： 实习研究员，中国医学科学院天津血液学研究所
1992－1996： 学士，南开大学生命科学院


2019/05– Professor, Shanghai TenthPeople's Hospital, School of Medicine, Advanced Institute for TranslationalMedicine, Tongji University
2013/02 – 2019/04 Professor,Advanced Institute for Translational Medicine, School of Life Sciences andTechnology, Tongji University
2004/08 – 2013/01 SeniorResearch Scientist, Research Associate, Research Scholar, Research Fellow, CellBiology Program, Sloan Kettering Institute, Memorial Sloan Kettering CancerCenter, New York, NY
2003 – 2004 ResearchFellow, Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences (SIBS), Chinese Academy of Sciences (CAS), P.R. China
1998 – 2003 PhDin Cell Biology, Institute of Biochemistry and Cell Biology, SIBS, CAS, P.R.China


1996 – 1998 ResearchAssistant, Institute of Hematology, Chinese Academy of Medical Sciences


1992– 1996 B.S. in Molecular Biology, Nankai University,P.R. China

肿瘤转移实验室于2013年2月在同济大学组建。实验室利用小鼠模型研究直肠癌、肺癌和乳腺癌等肿瘤转移复发的细胞和分子机制。试图在分子水平找到控制肿瘤转移各个步骤特异性的信号转导通路，绘制调控肿瘤转移的信号转导网络，揭示关键的信号转导分子，开发有效的分子靶向药物，为临床诊断和治疗提供靶点和干预手段。
1、利用肿瘤转移复发的小鼠模型，我们设计了一套高通量，全基因组水平的筛选模型，来寻找与肿瘤转移复发直接相关的分子。
2、利用肿瘤病人样品，从DNA、RNA、和蛋白水平，同时结合细胞和动物的功能相关实验，来捕获调控肿瘤转移复发的分子。
3、转化医学研究。针对以上研究所获得的关键信号转导分子，开发单克隆抗体或小分子化合物，进而最终能够在临床病人的诊断和治疗上获得应用。
上海“****”特聘专家（2014）、上海高校****（****）（2013）、国家自然科学二等奖（2007，第三完成人）、上海市自然科学一等奖（2006，第三完成人）、全国百篇优秀博士论文（2006）、中国细胞生物学学会优秀青年科技论文奖一等奖（2005）、明治乳业生命科学奖（2004）等等。

代表性文章：
1. Gao H#*, Chakraborty G*, Zhang Z, Akalay I, GadiyaM, Gao Y, Sinha S, Hu J, Jiang C, Akram M, Brogi E, Leitinger B, and GiancottiFG#. Multi-organ Site Metastatic Reactivation Mediated by Non-canonicalDiscoidin Domain Receptor 1 Signaling. Cell 2016;166(1):47-62.
[ResearchWatch in Cancer Discov.; Editor's Choice in Science Signaling;BoneKEy Watch in IBMS BONEKEY].
(# corresponding author) (* equalcontributions)

2. Gao H#, Chakraborty G, Lee-Lim AP, Mavrakis KJ,Wendel HG, and Giancotti FG#. Forward genetic screens in mice uncover mediatorsand suppressors of metastatic reactivation. Proc. Natl. Acad. Sci.USA 2014; 111 (46) 16532-16537.
(# corresponding author)

3. Gao H, Chakraborty G, Lee-Lim AP, Mo Q,Decker M, Vonica A, Shen R, Brogi E, Brivanlou AH, and GiancottiFG. The BMP Inhibitor Coco Reactivates Breast Cancer Cells at LungMetastatic sites. Cell 2012;150(4):764-79.
[Research Watch in Cancer Discov.; ResearchHighlight in Nat. Rev. Cancer; Editor’s Choice in The Scientist;Recommended F1000].

4. Guan J*, Xu ZZ*, Gao H, He SQ, Ma GQ, Sun T,Wang LH, Zhang ZN, Lena I, Kitchen I, Elde R, Zimmer A, He C, Pei G, Bao L, andZhang X. Interaction with vesicle luminal protachykinin regulates surfaceexpression of delta-opioid receptors and opioid analgesia. Cell 2005;122(4):619-31.
(* equal contributions)

5. Gao H*, Sun Y*, Wu Y, Luan B, Wang Y, Qu B,and Pei G. Identification of beta-arrestin 2 as a G-protein-coupledreceptor-stimulated regulator of NF-kappaB pathways. Mol. Cell 2004;14(3):303-17.
(* equal contributions)

6. Wang P*, Gao H*, Ni Y, Wang B, Wu Y, Ji L,Qin L, Ma L, and Pei G. Beta-Arrestin 2 functions as a G-protein-coupledreceptor-activated regulator of oncoprotein Mdm2. J. Biol.Chem. 2003;278: 6363-70.
(* equal contributions)




ResearchInterests:
1. Tounderstand the molecular and cellular mechanisms of cancer metastasis.
2.To develop novel therapeutic antibodies or chemical drugs for the treatment oftumor metastasis.

ResearchDescription:
Researchin the laboratory is focus on the molecular and cellular mechanisms of cancermetastasis and its translation into new therapies.
We have developed ahigh throughput platform for in vivo functional genetic screening.


1.Gain-of-functioncDNA library screens identify metastasis-promoting genes.


2.Loss-of-functiongenome-wide CRISPR/Cas9 library screens identify metastasis suppressorgenes.


3.Weare also combining genomic and proteomic analysis of human clinical samples,and functional testing in mouse model systems.

Honorsand Awards:
11/2014：“Shanghai 1000-TalentProgram”- Distinguished Professor
9/2013：Professor of Special Appointment (Eastern Scholar) atShanghai Institutions of Higher Learning
10/2007: National Natural Science Award,Second Prize, State Council
11/2006: Natural Science Award, First Prize,Shanghai Municipal Goverment
08/2006: National Top Hundred ExcellentDoctoral Dissertations Award in China
11/2005: Young Scientist Prize of ChineseSociety for Cell Biology, First Prize
11/2004: Life ScienceAward, SHANGHAI, MEIJI Dairies Corp

RepresentativePublication：
1. Gao H#*, Chakraborty G*, Zhang Z, Akalay I, GadiyaM, Gao Y, Sinha S, Hu J, Jiang C, Akram M, Brogi E, Leitinger B, and GiancottiFG#. Multi-organ Site Metastatic Reactivation Mediated by Non-canonicalDiscoidin Domain Receptor 1 Signaling. Cell 2016;166(1):47-62.
[ResearchWatch in Cancer Discov.; Editor's Choice in Science Signaling;BoneKEy Watch in IBMS BONEKEY].
(# corresponding author) (* equalcontributions)

2. Gao H#, Chakraborty G, Lee-Lim AP, Mavrakis KJ,Wendel HG, and Giancotti FG#. Forward genetic screens in mice uncover mediatorsand suppressors of metastatic reactivation. Proc. Natl. Acad. Sci.USA 2014; 111 (46) 16532-16537.
(# corresponding author)

3. Gao H, Chakraborty G, Lee-Lim AP, Mo Q,Decker M, Vonica A, Shen R, Brogi E, Brivanlou AH, and GiancottiFG. The BMP Inhibitor Coco Reactivates Breast Cancer Cells at LungMetastatic sites. Cell 2012;150(4):764-79.
[Research Watch in Cancer Discov.; ResearchHighlight in Nat. Rev. Cancer; Editor’s Choice in The Scientist; RecommendedF1000].

4. Guan J*, Xu ZZ*, Gao H, He SQ, Ma GQ, Sun T,Wang LH, Zhang ZN, Lena I, Kitchen I, Elde R, Zimmer A, He C, Pei G, Bao L, andZhang X. Interaction with vesicle luminal protachykinin regulates surfaceexpression of delta-opioid receptors and opioid analgesia. Cell 2005;122(4):619-31.
(* equal contributions)

5. Gao H*, Sun Y*, Wu Y, Luan B, Wang Y, Qu B,and Pei G. Identification of beta-arrestin 2 as a G-protein-coupledreceptor-stimulated regulator of NF-kappaB pathways. Mol. Cell 2004;14(3):303-17.
(* equal contributions)

6. Wang P*, Gao H*, Ni Y, Wang B, Wu Y, Ji L,Qin L, Ma L, and Pei G. Beta-Arrestin 2 functions as a G-protein-coupledreceptor-activated regulator of oncoprotein Mdm2. J. Biol.Chem. 2003;278: 6363-70.
(* equal contributions)